| BIOGEN INC. DL -,0005 |
| USA |
| Gesundheit |
| US09062X1037 / 789617 |
| IDP (Frankfurt) / BIIB (NASDAQ) |
| FRA:IDP, ETR:IDP, IDP:GR, NASDAQ:BIIB |
| https://www.biogen.com/ |
|
Biogen Inc. is a multinational biotechnology company focused on the discovery, development, and delivery of therapies for neurological, autoimmune, and rare diseases. Its marketed portfolio features multiple sclerosis treatments including Avonex, Tys..
>Volltext.. |
| 23365.62 Mio. EUR |
| 25784.16 Mio. EUR |
| 8258.66 Mio. EUR |
| 2772.55 Mio. EUR |
| 1120.06 Mio. EUR |
| 7.65 EUR |
| 5767.58 Mio. EUR |
| 2606.31 Mio. EUR |
| 1909.88 Mio. EUR |
| 1.14 |
| -9.32% |
| -30.19% |
| - |
| - |
| - |
| - |
| BIOGEN |
| 04.04.26 |
|